Published in N Engl J Med on December 25, 2008
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol (2010) 1.83
ANCA-associated vasculitides--advances in pathogenesis and treatment. Nat Rev Rheumatol (2010) 1.67
Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) (2014) 1.65
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol (2011) 1.52
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) (2010) 1.45
Update on diffuse alveolar hemorrhage and pulmonary vasculitis. Immunol Allergy Clin North Am (2012) 1.07
Interstitial Lung Disease in Children Older Than 2 Years. Pediatr Allergy Immunol Pulmonol (2010) 1.06
Microscopic polyangiitis. Rheum Dis Clin North Am (2010) 0.99
Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther (2009) 0.99
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2013) 0.98
Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) (2014) 0.96
Management of ANCA-associated vasculitis: Current trends and future prospects. Ther Clin Risk Manag (2010) 0.93
Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther (2012) 0.93
Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Immunol (2011) 0.91
Central nervous system vasculitis: still more questions than answers. Curr Neuropharmacol (2011) 0.90
Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol (2011) 0.90
The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. Clin Kidney J (2015) 0.88
Non-infectious orbital vasculitides. Eye (Lond) (2012) 0.88
Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect (2011) 0.87
Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis. J Am Soc Nephrol (2015) 0.87
Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis. Kidney Int Suppl (2011) (2012) 0.86
Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? Nephrol Dial Transplant (2015) 0.84
Treatment of renal manifestations of ANCA-associated vasculitis. J Nephropathol (2013) 0.84
Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides. Arthritis Res Ther (2011) 0.83
[Treatment strategies for ANCA-associated vasculitides]. Z Rheumatol (2015) 0.82
Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis). Ther Clin Risk Manag (2014) 0.82
ANCA-associated vasculitides-lessons from the adult literature. Pediatr Nephrol (2010) 0.82
[ANCA-associated vasculitis]. Z Rheumatol (2013) 0.81
Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther (2015) 0.81
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol (2015) 0.81
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol (2014) 0.80
Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore) (2014) 0.80
ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol (2016) 0.80
Maintenance of clinical remission in ANCA-associated vasculitis. Nat Rev Rheumatol (2012) 0.78
Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol (2010) 0.78
A physician survey reveals differences in management of idiopathic pulmonary hemosiderosis. Orphanet J Rare Dis (2015) 0.78
Immune mediated diseases and immune modulation in the neurocritical care unit. Neurotherapeutics (2012) 0.78
Granulomatosis With Polyangiitis in Otolaryngologist Practice: A Review of Current Knowledge. Clin Exp Otorhinolaryngol (2016) 0.78
Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis. Indian J Nephrol (2016) 0.76
Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis. Clin Exp Rheumatol (2016) 0.76
Gastrointestinal aspects of vasculitides. Nat Rev Gastroenterol Hepatol (2016) 0.76
Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic glomerulonephritis. Clin Exp Nephrol (2013) 0.75
ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study. BMC Nephrol (2015) 0.75
Linking classification and therapeutic management of vasculitides. Arthritis Res Ther (2015) 0.75
Practice patterns of ANCA-associated vasculitis: exploring differences among subspecialties at a single academic medical centre. Clin Exp Rheumatol (2014) 0.75
Updates in ANCA-associated vasculitis. Eur J Rheumatol (2016) 0.75
Understanding the role of rituximab in ANCA GN: regressing toward the mean. J Am Soc Nephrol (2014) 0.75
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med (2009) 0.75
Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. Immunotargets Ther (2015) 0.75
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med (2009) 0.75
Vasculitis syndromes: vasculitis therapy--between Scylla and Charybdis. Nat Rev Rheumatol (2009) 0.75
Sequential strokes in a hyperacute stroke unit. JRSM Open (2014) 0.75
Vasculitis syndromes: which maintenance therapy for ANCA vasculitis? Nat Rev Nephrol (2009) 0.75
Risk Factors and Adverse Events Poorly Predict Infections and Hypogammaglobulinemia in Granulomatosis with Polyangiitis Patients Receiving Rituximab. Autoimmune Dis (2016) 0.75
Recent advances in understanding and treating vasculitis. F1000Res (2016) 0.75
Clinical trial for Japanese patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis: the JMAAV study. Clin Exp Nephrol (2013) 0.75
Treatment of primary systemic necrotizing vasculitides: the role of biotherapies. Clin Exp Nephrol (2013) 0.75
Risk of liver disease in methotrexate treated patients. World J Hepatol (2017) 0.75
Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis. RMD Open (2017) 0.75
Issues in trial design for ANCA-associated and large-vessel vasculitis. Nat Rev Rheumatol (2014) 0.75
Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int (2017) 0.75
Clinical Trials in Vasculitis. Curr Treatm Opt Rheumatol (2016) 0.75
Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases. Clin Rheumatol (2017) 0.75
Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis. Clin Rev Allergy Immunol (2017) 0.75
Birmingham vasculitis activity score at diagnosis is a significant predictor of relapse of polyarteritis nodosa. Rheumatol Int (2017) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med (2002) 7.00
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med (2014) 5.98
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation (2010) 5.87
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
Whipple's disease. N Engl J Med (2007) 4.46
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis (2006) 3.68
Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum (2001) 3.67
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum (2011) 3.60
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum (2002) 3.55
Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med (2005) 3.49
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum (2005) 3.44
Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum (2012) 3.38
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
The systemic capillary leak syndrome: a case series of 28 patients from a European registry. Ann Intern Med (2011) 2.88
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv (2013) 2.65
Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med (2004) 2.64
Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol (2008) 2.60
CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood (2011) 2.59
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum (2004) 2.44
Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest (2009) 2.40
A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol (2004) 2.36
Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med (2014) 2.36
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35
Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med (2002) 2.35
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost (2007) 2.32
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum (2013) 2.28
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum (2008) 2.26
Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol (2014) 2.24
Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J (2012) 2.22
Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis (2010) 2.21
Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum (2010) 2.11
Granulomatosis-associated common variable immunodeficiency disorder: a case-control study versus sarcoidosis. Eur Respir J (2012) 2.11
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis (2010) 2.09
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood (2008) 2.07
The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) (2011) 2.05
Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) (2005) 2.03
Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum (2004) 2.01
HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum (2009) 2.00
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol (2015) 1.98
Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum (2007) 1.97
Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol (2002) 1.91
ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant (2005) 1.84
Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis (2012) 1.84
Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum (2007) 1.83
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood (2007) 1.83
Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore) (2009) 1.81
Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease). Respiration (2007) 1.79
Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum (2003) 1.78
Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine (2006) 1.77
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77
Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) (2009) 1.76
Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol (2002) 1.76
Churg-Strauss syndrome. Curr Opin Rheumatol (2007) 1.76